Clobetasol propionate, a highly potent topical corticosteroid used in the treatment of inflammatory skin disorders such as psoriasis and eczema, was developed in the 1970s and introduced into medical use as part of a new generation of high-potency dermatologic therapies. Its history is marked by strong clinical effectiveness in rapidly reducing inflammation, itching, and plaque formation, particularly in resistant dermatoses, which led to its widespread adoption in dermatology.

BRAND NAMES

Clobetasol propionate is sold under several brand names worldwide, depending on the country and formulation (cream, ointment, scalp solution, shampoo, foam, etc.).

Common brand names include:

  • Temovate (widely used in the United States) 
  • Dermovate (commonly used in the United Kingdom and many other countries)

MECHANISM OF ACTION

Clobetasol propionate is a very potent topical corticosteroid that works by binding to glucocorticoid receptors in skin cells and altering gene expression to reduce inflammation. It suppresses the production of inflammatory mediators like prostaglandins and leukotrienes by inhibiting phospholipase A2 and decreasing cytokine release. This leads to reduced redness, swelling, itching, and immune activity in the affected skin areas.

PHARMACOKINETICS

Absorption

Clobetasol propionate is absorbed through the skin in small amounts, with absorption increasing in damaged or thin skin. Using it over large areas, for long periods, or under occlusion can increase systemic absorption and may lead to side effects like HPA axis suppression.

Distribution

For Clobetasol propionate, the volume of distribution (Vd) after topical use is not well defined/very low systemically, because only a small fraction enters systemic circulation.

  • Reported systemic Vd (approx., if absorbed): ~1–2 L/kg

  • Clinical relevance: minimal systemic distribution at normal topical doses

Metabolism

Clobetasol propionate is primarily metabolized in the liver after systemic absorption. It undergoes oxidation and reduction reactions, leading to inactive metabolites that are further conjugated and eliminated. Because only a small amount is absorbed through the skin under normal use, systemic metabolism is usually limited.

Elimination

Clobetasol propionate is eliminated mainly through hepatic metabolism followed by excretion of inactive metabolites in the urine and bile. Only a very small amount of unchanged drug is excreted. Its elimination is usually limited because systemic absorption from topical use is low under normal conditions.

PHARMACODYNAMICS

  • Penetrates skin cells and binds to glucocorticoid receptors in the cytoplasm

  • Drug–receptor complex moves into the cell nucleus

  • Modulates gene transcription (upregulates anti-inflammatory proteins, downregulates pro-inflammatory genes)

  • Inhibits release of inflammatory mediators like cytokines, prostaglandins, leukotrienes

  • Reduces migration and activity of immune cells (T cells, macrophages, eosinophils)

  • Final effect: reduced inflammation, itching, and skin immune response

ADMINISTRATION

Clobetasol propionate is applied topically to the affected skin or scalp in a thin layer, usually once or twice daily as prescribed. It is intended for short-term use only due to its high potency and should be used carefully to avoid over-application or use on large body areas.

DOSAGE AND STRENGTH

Clobetasol propionate is available in 0.05% strength in forms like cream, ointment, lotion, gel, foam, and shampoo. It is applied in a thin layer once or twice daily for short-term use, usually not exceeding two weeks or the recommended weekly amount to reduce the risk of side effects.

DRUG INTERACTIONS

  • Minimal interactions due to low topical systemic absorption

  • Increased risk when used with other corticosteroids (additive steroid effects)

  • CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) may increase systemic steroid levels if absorption occurs

  • Occlusive dressings or damaged skin can increase absorption and interaction risk

  • Caution with long-term or high-dose use due to possible HPA axis suppression

FOOD INTERACTIONS

Clobetasol propionate has no clinically significant food interactions because it is applied topically and has minimal systemic absorption under normal use. However, if used extensively or over large areas, systemic absorption may increase slightly, but food intake still does not meaningfully affect its action or safety.

CONTRAINDICATIONS

  • Hypersensitivity to clobetasol or any formulation component 

  • Untreated bacterial, viral, or fungal skin infections (e.g., herpes, varicella, tinea) 

  • Rosacea and perioral dermatitis 

  • Use on facial acne or acne vulgaris 

  • Primary skin infections without appropriate antimicrobial therapy

SIDE EFFECTS

  • Skin thinning (atrophy)

  • Burning or stinging sensation

  • Itching or irritation

  • Dry skin

  • Stretch marks (striae)

OVER DOSE

Clobetasol propionate overdose is usually due to overuse or long-term application, leading to skin thinning and irritation, and in severe cases systemic effects like adrenal suppression

TOXICITY

Clobetasol propionate toxicity is usually due to overuse or long-term application and can cause skin thinning and irritation, and in severe cases systemic effects like adrenal suppression.